TOXOPLASMA GONDII SERINE PROTEASE INHIBITOR-1 (TgPI-1) DIFFERENTIALLY MODULATES DENDRITIC CELL SUBSETS

JOEL KATÁN; JULIETA SANTOS; VALENTINA MARTIN; PAULA BERGUER; IGNACIO FENOY; ARIADNA SOTO; ALEJANDRA GOLDMAN

Mar del plata

Congreso; Reunion Anual Biociencias 2022- reunion SAI FAIC; 2022

BACKGROUND: We previously showed that treatment with T. gondii serine protease inhibitor-1 (TgPI-1) significantly reduced experimental asthma. BMDC differentiated in the presence of TgPI-1 (DCTgPI-1) significantly lowered IL-12 secretion, CD80 and CD86 expression and increased PDL-1 and CD45Rb. AIM: Further characterize TgPI-1 effect on dendritic cells (DCs) in vitro by analyzing the T response profile promoted by DCTgPI-1 and in vivo after treating asthmatic mice with TgPI-1. METHODS: BMDCs were obtained from BALB/c mice bone-marrow cultured with GM-CSF in presence or not of TgPI-1 and stimulated with LPS. Then a mixed lymphocyte reaction (MLR) was done co-culturing CD11c+ cells with naive C57BL/6 mice splenocytes. For in vivo study, BALB/c mice were ip. sensitized with OVA/Alum and aerosol challenged. Later, were intranasally treated with TgPI-1+OVA (OPI). Controls included naive, and sensitized mice treated with OVA (OO). Eight h later, cDC1 (MHCII+CD11c+CD103+), cDC2 (MHCII+CD11c+CD11b+CD64-) and moDCs (MHCII+CD11c+CD11b+CD64+) were assessed by flow cytometry in lung and lymph nodes. RESULTS: MLR supernatants from DCrTgPI-1, showed significantly less IL-4 and IL-17 (p